RxDoctor Payments Data

Mario Fatigati, MD

Internal Medicine · Bridgeville, PANPI 1083677215

Payments from drug & device makers

$1,010in general payments, 2019–2025

Across 69 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$204
  • Johnson & Johnson$151
  • AbbVie$110
  • Lilly USA, LLC$107
  • Daiichi Sankyo Inc.$64
  • Novo Nordisk$59
  • plus $316 from 12 others

What the payments were for

  • Food & beverage$1,00599%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,010 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,803
Medicare patients
245
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$227,745
JardianceEmpagliflozin105$73,635
OzempicSemaglutide45$42,142
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$33,920
FarxigaDapagliflozin Propanediol59$31,744
XareltoRivaroxaban78$29,281
TrulicityDulaglutide25$23,269
TradjentaLinagliptin56$19,070
Breo ElliptaFluticasone/Vilanterol37$16,132
EntrestoSacubitril/Valsartan28$15,117
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog71$14,761
Spiriva RespimatTiotropium Bromide23$12,967
Atorvastatin Calcium786$9,386
XiidraLifitegrast11$8,285
JanuviaSitagliptin Phosphate27$7,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$227,745513 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$204$55,633101 claims
Novo NordiskOzempic$59$42,14245 claims
AstraZenecaFarxiga$48$31,74459 claims
Johnson & JohnsonXarelto$151$29,28178 claims
Lilly USA, LLCTrulicity$107$23,26925 claims
NovartisEntresto$27$15,11728 claims
MerckJanuvia$42$7,70927 claims
AbbVieLumigan$110$4,62917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bridgeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →